According to a news source, the Indian Pharmaceutical Alliance (IPA) has challenged U.S. allegations that India’s Patent Act discriminates against foreign companies, pointing to the increased revenues and market capitalization in India for several U.S. companies since the law was amended in 2005 to conform to the World Trade Organization’s (WTO’s) agreement on intellectual property rights (TRIPS). IPA has suggested that the United States resort to WTO dispute resolution mechanisms if it believes India has violated TRIPS. IPA Secretary General D.G. Shah reportedly said, “We are not aware of any provision in India’s patent law that discriminates against US companies or, for that matter, any company based on its domicile for the grant [or] refusal of patents.” Several U.S. lawmakers and pharmaceutical companies have apparently expressed concern about Section 3(d) of the law which does not allow patents to issue for already known drugs where the new claims do not provide greater efficacy. See The Economic Times, August 25, 2013.